Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...
- Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus ...
LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback